BRPI1010738A8 - Derivados de aminotriazol fluorado - Google Patents

Derivados de aminotriazol fluorado

Info

Publication number
BRPI1010738A8
BRPI1010738A8 BRPI1010738A BRPI1010738A BRPI1010738A8 BR PI1010738 A8 BRPI1010738 A8 BR PI1010738A8 BR PI1010738 A BRPI1010738 A BR PI1010738A BR PI1010738 A BRPI1010738 A BR PI1010738A BR PI1010738 A8 BRPI1010738 A8 BR PI1010738A8
Authority
BR
Brazil
Prior art keywords
aminotriazole derivatives
fluorinated aminotriazole
fluorinated
derivatives
formula
Prior art date
Application number
BRPI1010738A
Other languages
English (en)
Portuguese (pt)
Inventor
Bur Daniel
Corminboeuf Olivier
Cren Sylvaine
Grisostomi Corinna
Leroy Xavier
Richard-Bildstein Sylvia
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI1010738A2 publication Critical patent/BRPI1010738A2/pt
Publication of BRPI1010738A8 publication Critical patent/BRPI1010738A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
BRPI1010738A 2009-06-09 2010-06-07 Derivados de aminotriazol fluorado BRPI1010738A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2009052445 2009-06-09
PCT/IB2010/052509 WO2010143116A1 (en) 2009-06-09 2010-06-07 Fluorinated aminotriazole derivatives

Publications (2)

Publication Number Publication Date
BRPI1010738A2 BRPI1010738A2 (pt) 2016-03-15
BRPI1010738A8 true BRPI1010738A8 (pt) 2017-12-26

Family

ID=42371383

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010738A BRPI1010738A8 (pt) 2009-06-09 2010-06-07 Derivados de aminotriazol fluorado

Country Status (22)

Country Link
US (1) US8580831B2 (enExample)
EP (1) EP2440555B1 (enExample)
JP (2) JP5095035B2 (enExample)
KR (1) KR101444559B1 (enExample)
CN (1) CN102414207B (enExample)
AR (1) AR077032A1 (enExample)
AU (1) AU2010258334B2 (enExample)
BR (1) BRPI1010738A8 (enExample)
CA (1) CA2760588C (enExample)
CL (1) CL2011003097A1 (enExample)
ES (1) ES2587139T3 (enExample)
IL (1) IL216792A (enExample)
MA (1) MA33420B1 (enExample)
MX (1) MX342440B (enExample)
MY (1) MY161243A (enExample)
NZ (1) NZ597453A (enExample)
PL (1) PL2440555T3 (enExample)
RU (1) RU2544862C2 (enExample)
SG (1) SG175363A1 (enExample)
TW (1) TWI404717B (enExample)
WO (1) WO2010143116A1 (enExample)
ZA (1) ZA201200127B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
RU2492167C2 (ru) 2007-12-18 2013-09-10 Актелион Фармасьютиклз Лтд Производные аминотриазола в качестве агонистов alх
AU2010250789B2 (en) 2009-05-18 2015-05-14 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists
CA2760887A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists
KR101905927B1 (ko) 2010-11-17 2018-10-08 이도르시아 파마슈티컬스 리미티드 가교된 스피로［２．４］헵탄 에스테르 유도체
CN103261194B (zh) 2010-12-07 2016-02-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑基-甲醚衍生物
KR101847672B1 (ko) * 2010-12-07 2018-04-10 이도르시아 파마슈티컬스 리미티드 Alx 수용체 작용제로서의 히드록실화 아미노트리아졸 유도체
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CA2871334A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
EA201500399A1 (ru) 2012-10-10 2015-09-30 Актелион Фармасьютиклз Лтд. Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
US10370451B2 (en) 2013-04-22 2019-08-06 The University Of Tokyo Preventive or therapeutic agent for inflammatory disease
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
WO2015007830A1 (en) 2013-07-18 2015-01-22 Actelion Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
JP7763513B2 (ja) 2021-06-01 2025-11-04 アズキュリス カンパニー，リミテッド 新規オキサゾール誘導体、及びそれを含むアレルギー性疾患の予防又は治療用薬学的組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
KR20030030029A (ko) 2000-09-22 2003-04-16 니혼노야쿠가부시키가이샤 Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
WO2003082314A2 (en) 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
TWI335913B (en) * 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
EP1692502A2 (en) 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
CN101039933B (zh) * 2004-09-17 2012-06-06 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的二氨基三唑化合物
US20060293288A1 (en) 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
WO2007055941A2 (en) 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
EP2195656A4 (en) 2007-08-21 2011-10-19 Senomyx Inc HUMAN T2R BITTERITY RECEPTORS AND USES THEREOF
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
RU2492167C2 (ru) * 2007-12-18 2013-09-10 Актелион Фармасьютиклз Лтд Производные аминотриазола в качестве агонистов alх
AU2010250789B2 (en) 2009-05-18 2015-05-14 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists
CA2760887A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists

Also Published As

Publication number Publication date
NZ597453A (en) 2013-03-28
CA2760588C (en) 2017-08-08
JP5095035B2 (ja) 2012-12-12
CN102414207A (zh) 2012-04-11
MX342440B (es) 2016-09-29
TW201102383A (en) 2011-01-16
AU2010258334A1 (en) 2012-02-02
KR20120089380A (ko) 2012-08-09
RU2544862C2 (ru) 2015-03-20
CN102414207B (zh) 2015-09-30
CA2760588A1 (en) 2010-12-16
IL216792A0 (en) 2012-02-29
SG175363A1 (en) 2011-12-29
MA33420B1 (fr) 2012-07-03
ZA201200127B (en) 2014-06-25
US20120101138A1 (en) 2012-04-26
CL2011003097A1 (es) 2012-07-06
AU2010258334B2 (en) 2015-02-26
BRPI1010738A2 (pt) 2016-03-15
TWI404717B (zh) 2013-08-11
EP2440555A1 (en) 2012-04-18
JP2012255002A (ja) 2012-12-27
JP5775496B2 (ja) 2015-09-09
IL216792A (en) 2014-05-28
JP2012529491A (ja) 2012-11-22
WO2010143116A1 (en) 2010-12-16
MY161243A (en) 2017-04-14
US8580831B2 (en) 2013-11-12
EP2440555B1 (en) 2016-05-18
PL2440555T3 (pl) 2016-11-30
ES2587139T3 (es) 2016-10-20
KR101444559B1 (ko) 2014-09-26
AR077032A1 (es) 2011-07-27
MX2011012739A (es) 2011-12-16

Similar Documents

Publication Publication Date Title
BRPI1010738A8 (pt) Derivados de aminotriazol fluorado
BR112014011055A2 (pt) novos derivados de [1,2,3]triazolo[4,5-d]pirimidina
BR112012024199A2 (pt) derivados de n-(imidazopirimidin-7-il)-heteroarilamida e seu uso como inibidores de pde10a
SV2009003376A (es) Derivados de aril isoxazolinas insecticidas
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
BR112012000763B8 (pt) compostos derivados de piridin-4-il, composição farmacêutica, e, usos de um composto
SV2010003472A (es) Compuestos de pirazol
BR112014012479A2 (pt) derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas das agonistas de receptor 2 de canabinóide
MX2016006336A (es) Compuestos pirazolopirimidina.
BR112015009600A2 (pt) piridina-2-amidas úteis como agonistas cb2
BR112013020270A2 (pt) derivados de pirazol microbicidas
JO3577B1 (ar) صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
BR112015023161A2 (pt) derivados de piridin-4-ila
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
BR112013033568A2 (pt) compostos éter amidopiridil e composições e seu uso contra parasitas
DOP2011000245A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
UY32757A (es) Derivados de pirazoles, su preparacion y su aplicacion terapeutica
NI201000089A (es) Derivados de pirazol como inhibidores de 5-lo.
CU20130072A7 (es) 1 h-pirazol-5-olato sódico sustituido
CY1109865T1 (el) Συνθεσεις βαλσαρτανης
BR112012013005A2 (pt) compostos químicos e seu uso como pesticidas.
BR112015010469A2 (pt) derivados de imidazopiridina
ECSP078024A (es) Inhibidores de la adenilato ciclasa soluble

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]